EUVIMEDObjevte EUVIMED
Crossref

Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen

Gigyo Seo, Saeyoon Kim, Jun Chul Byun, Soonhak Kwon, Yun Jeong Lee

Brain and Development · 2023

DOI: 10.1016/j.braindev.2023.07.005 ↗

At a glance

Journal article in Brain and Development, 2023. Written by Gigyo Seo and 4 co-authors. Institution: Department of Pediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea. Major MEDLINE topics: Muscular Atrophy, Spinal, Spinal Muscular Atrophies of Childhood. Cited 16 times so far (Crossref); 31 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

BACKGROUND: This study aimed to evaluate the neurofilament light chain (NfL) as a biomarker for treatment responses in children with a broad spectrum of spinal muscular atrophy (SMA) under nusinersen treatment. METHOD: We measured NfL levels in serum (sNfL) and cerebrospinal fluid (cNfL) in nusinersen-treated patients with SMA and children without neurologic disorders. Correlations between cNfL and sNfL levels and motor function scores were analyzed. RESULTS: sNfL and cNfL levels were measured in eight patients with SMA (SMA type 1, n = 3; SMA type 2, n = 5). sNfL levels were strongly correlated with cNfL levels regardless of the SMA subtype (r = 0.97, P < 0.001). Patients with SMA type 1 had higher baseline cNfL and sNfL levels before treatment initiation than those with SMA type 2 and neurologically healthy children. In patients with acute stage of SMA type 1 and 2, the NfL level rapidly decreased during the nusinersen treatment loading phase followed by stabilization at a lower plateau level. In contrast, in a patient with a chronic stage of SMA type 2, the NfL level remained within the normal range with no apparent downward trend. Motor function scores showed a tendency toward an inverse correlation with NfL levels in patients with acute stage although not in patients with chronic stage. CONCLUSIONS: cNfL and sNfL levels can be promising biomarkers for monitoring treatment response in patients within their acute stage, particularly in SMA type 1, although not in patients with a chronic stage of SMA type 2.

Subjects

MeSH terms (MEDLINE)

Muscular Atrophy, SpinalSpinal Muscular Atrophies of ChildhoodHumansChildIntermediate FilamentsOligonucleotidesBiomarkers

Author keywords

BiomarkerNeurofilament light chainNusinersenSpinal muscular atrophyTreatment

Substances

nusinersenOligonucleotidesBiomarkers

Authors and institutions

  • Department of Pediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.
  • Department of Pediatrics, School of Medicine, Yeungnam University, Daegu, South Korea.
  • Department of Pediatrics, School of Medicine, Keimyung University, Daegu, South Korea.
  • Department of Pediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea. Electronic address: oilily1103@hanmail.net.

Cite

APA

Seo, G., Kim, S., Byun, J. C., Kwon, S., & Lee, Y. J. (2023). Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen. Brain and Development. https://doi.org/10.1016/j.braindev.2023.07.005

Vancouver

Seo G, Kim S, Byun JC, Kwon S, Lee YJ. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen. Brain and Development. 2023. doi:10.1016/j.braindev.2023.07.005

BibTeX
@article{Seo2023,
  author = {Seo, Gigyo and Kim, Saeyoon and Byun, Jun Chul and Kwon, Soonhak and Lee, Yun Jeong},
  title = {Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen},
  journal = {Brain and Development},
  year = {2023},
  doi = {10.1016/j.braindev.2023.07.005}
}
Start for free →